Engineered immune cells take aim at stubborn leukemia after transplant

NCT ID NCT07280494

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests a new treatment called CD7-targeted CAR-T cells for people with T-lymphoblastic leukemia or lymphoma that remains after a stem cell transplant. The therapy uses a patient's own or a donor's immune cells, modified to find and destroy cancer cells. The study will enroll 18 participants to check safety and how well it clears the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CD7-targeted CAR-T cells (a type of immune cell therapy)
What this could lead to: If successful, this could offer a new treatment option for patients with lingering leukemia or lymphoma after a stem cell transplant, potentially improving survival.
What could go wrong: This is a very early (Phase 1) and small trial (18 people), so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CD7+ T-ALL/LBL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lymphoma Neoplasm, Residual T lymphoblastic leukemia/lymphoma T-cell acute lymphoblastic leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CD7+ T-ALL/LBL

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, China, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.